Valneva Stock Under Pressure at €2.40: Down 40% in Three Months, Testing Support
The stock of the Nantes-based vaccine specialist continues to decline mid-morning this Friday, May 8, as the CAC 40 drops 0.83% during the session. Valneva falls 2.08% to €2.40, following a downward trend that has wiped out more than 40% of its value over three months.
Another Session in the Red, Stock at the Bottom of the SBF 120
The stock is among the top five declines in the SBF 120 during the session, ranking 117th out of 120 listed values. The biotech drops 2.08% while the broader index falls 0.79%. Over seven sessions, the stock still shows a gain of 3.76%, indicating an attempt to stabilize after a prolonged fall. The three-month decline remains massive at 40.44%, and the annual performance stands at -18.07%. The session unfolds in a pressured Parisian market, with the European healthcare sector also moving into negative territory, as exemplified by Sanofi dropping 1.26%.
Stock Stalls Between Support at €2.26 and Deteriorating Moving Averages
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The stock is trading in the lower part of its Bollinger Bands, close to the technical support identified at €2.26. This level was already tested during the session on May 4, following the capital increase of 84 million euros completed at the end of April. The RSI at 37 indicates a selling momentum still in place, without reaching the oversold zone. The price remains far from its moving averages: the MM50 at €3.37 and the MM200 at €3.88 confirm a deteriorated trend in the medium and long term. On the agenda, the next key event is the Bernstein European Small & Mid-Cap Conference scheduled for May 21, 2026, before the general assembly on June 1.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
